Abstract

BackgroundRelapses occur in about 20% of children with acute lymphoblastic leukemia (ALL). Approximately one-third of these children can be cured. Their risk for late effects is high because of intensified treatment, but their health-related quality of life (HRQOL) was largely unmeasured. Our aim was to compare HRQOL of ALL survivors with the general population, and of relapsed with non-relapsed ALL survivors.Methodology/Principal FindingsAs part of the Swiss Childhood Cancer Survivor Study (SCCSS) we sent a questionnaire to all ALL survivors in Switzerland who had been diagnosed between 1976–2003 at age <16 years, survived ≥5 years, and were currently aged ≥16 years. HRQOL was assessed with the Short Form-36 (SF-36), which measures four aspects of physical health and four aspects of mental health. A score of 50 corresponded to the mean of a healthy reference population. We analyzed data from 457 ALL survivors (response: 79%). Sixty-one survivors had suffered a relapse. Compared to the general population, ALL survivors reported similar or higher HRQOL scores on all scales. Survivors with a relapse scored lower in general health perceptions (51.6) compared to those without (55.8;p=0.005), but after adjusting for self-reported late effects, this difference disappeared.Conclusion/SignificanceCompared to population norms, ALL survivors reported good HRQOL, even after a relapse. However, relapsed ALL survivors reported poorer general health than non-relapsed. Therefore, we encourage specialists to screen for poor general health in survivors after a relapse and, when appropriate, specifically seek and treat underlying late effects. This will help to improve patients’ HRQOL.

Highlights

  • Acute lymphoblastic leukemia (ALL) is the most common cancer in children younger than 15 years of age, accounting for about 28% of malignancies in the pediatric population [1,2]

  • Ethics Statement Since 2004, all patients and their families give informed consent at the time of cancer diagnosis for their data to be included in the Swiss Childhood Cancer Registry (SCCR) and used for research

  • The questionnaire survey of the Swiss Childhood Cancer Survivor Study was approved by the ethics committee of the canton of Bern

Read more

Summary

Introduction

Acute lymphoblastic leukemia (ALL) is the most common cancer in children younger than 15 years of age, accounting for about 28% of malignancies in the pediatric population [1,2]. The disease and its treatment put ALL survivors are at risk for somatic and neuropsychological late effects and second malignancies [7,8,9,10,11]. This is true of survivors of relapsed ALL, who more frequently develop more severe chronic medical conditions, affecting more organ systems, than non-relapsed ALL survivors. One-third of these children can be cured Their risk for late effects is high because of intensified treatment, but their health-related quality of life (HRQOL) was largely unmeasured. Our aim was to compare HRQOL of ALL survivors with the general population, and of relapsed with non-relapsed ALL survivors

Objectives
Methods
Results
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call